J.Safra Asset Management Corp Cytokinetics Inc Transaction History
J.Safra Asset Management Corp
- $1.16 Billion
- Q1 2025
A detailed history of J.Safra Asset Management Corp transactions in Cytokinetics Inc stock. As of the latest transaction made, J.Safra Asset Management Corp holds 2,870 shares of CYTK stock, worth $95,083. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,870
Previous 1,751
63.91%
Holding current value
$95,083
Previous $82,000
40.24%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$486 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$393 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$330 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$265 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$202 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.12B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...